GlassScriptPhysician profile
Amanda R Bibbs
NPI 1609396944
$2,972.89
in general payments reported to CMS, 2019-2025
10 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.46 · 2022: $380 · 2023: $788 · 2024: $687 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,524.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $735.40 | 2021-2025 | Tavneos, Otezla, Uplizna |
| Astrazeneca Pharmaceuticals LP | $575.23 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $458.13 | 2023-2025 | Benlysta |
| Janssen Biotech, INC. | $374.78 | 2021-2025 | Simponi Aria, Tremfya, Stelara |
| Abbvie INC. | $338.04 | 2023-2025 | |
| Ucb, INC. | $223.18 | 2021-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $115.25 | 2022 | |
| Novartis Pharmaceuticals Corporation | $85.06 | 2025 | |
| Lundbeck LLC | $47.50 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $20.32 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Bibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.